Back to search
Plasmodium Falciparum Malaria (Uncomplicated)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Plasmodium Falciparum Malaria (Uncomplicated) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Plasmodium Falciparum Malaria (Uncomplicated) trials you may qualify forThis study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemethe…
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT ar…
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity. Estimates o…
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium…
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lum…